文献速递妇科生殖医学

复发性卵巢癌患者对芦卡帕利长期应答的特征分析

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-09-30

该事后分析汇总Study 10与ARIEL2两项研究,纳入545例高级别复发性卵巢癌患者,按RECIST应答持续时间分为长期(≥1年)、中期(6个月至<1年)和短期(<6个月)应答。结果显示27.5%的应答者获得长期应答,长期应答者多携带BRCA突变,BRCA结构变异与更长的应答持续时间相关。

要点

  • 27.5%(38/138)的应答者获得≥1年的长期应答。
  • 长期应答者中71.1%(27/38)携带BRCA1或BRCA2突变。
  • BRCA结构变异患者应答持续时间显著长于其他突变类型。

核心结论

  • 对芦卡帕利应答的患者中相当比例获得持续≥1年的应答。
  • 应答持续时间与分子特征相关,如存在逆转抵抗的BRCA结构变异。

研究设计与样本

  • 事后分析,汇总Study 10(NCT01482715;Parts 2A和2B;n=54)与ARIEL2(NCT01891344;Parts 1和2;n=491)两项研究。
  • 按研究者评估的RECIST完全或部分应答,根据应答持续时间(DOR)分为长期(≥1年)、中期(6个月至<1年)和短期(<6个月)。
  • 采用下一代测序检测肿瘤中的有害突变和杂合性缺失(LOH)。

主要发现

  • 入组患者中25.3%(138/545)为应答者。
  • 应答者中27.5%(38/138)为长期应答,28.3%(39/138)为中期应答,34.8%(48/138)为短期应答。
  • 长期应答者中71.1%(27/38)携带BRCA1或BRCA2突变,BRCA结构变异在长期应答者中最常见(14.8%;4/27)。
  • 携带BRCA结构变异的应答者(n=5)DOR显著长于其他突变类型患者(n=81;中位未达到 vs 0.62年;HR 0.21;95%CI 0.10-0.43;未校正p=0.014)。
  • BRCA野生型应答者中,长期和中期应答者多具有高全基因组LOH:分别为81.8%(9/11)和76.9%(10/13),包括7例携带RAD51C、RAD51D或CDK12有害突变。

临床怎么用

  • 对复发性高级别卵巢癌患者,芦卡帕利治疗前可考虑检测BRCA突变类型(含结构变异)及LOH状态以评估应答持续时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. METHODS: This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), intermediate (6 months to <1 year), or short (<6 months). Next-generation sequencing was used to detect deleterious mutations and loss of heterozygosity (LOH) in tumors. RESULTS: Overall, 25.3% (138/545) of enrolled patients were responders. Of these, 27.5% (38/138) had long-term responses; 28.3% (39/138) were intermediate- and 34.8% (48/138) were short-term responders. Most of the long-term responders harbored a BRCA1 or BRCA2 (BRCA) mutation (71.1%, 27/38), and BRCA structural variants were most frequent among long-term responders (14.8%; 4/27). Responders with HGOC harboring a BRCA structural variant (n = 5) had significantly longer DOR than patients with other mutation types (n = 81; median not reached vs 0.62 years; HR, 0.21; 95% CI, 0.10-0.43; unadjusted p = 0.014). Among responders with BRCA wild-type HGOC, most long- and intermediate-term responders had high genome-wide LOH: 81.8% (9/11) and 76.9% (10/13), respectively, including 7 with deleterious RAD51C, RAD51D, or CDK12 mutations. CONCLUSION: Among patients who responded to rucaparib, a substantial proportion achieved responses lasting ≥1 year. These analyses demonstrate the relationship between DOR to PARP inhibitor treatment and molecular characteristics in HGOC, such as presence of reversion-resistant BRCA structural variants.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Swisher EM, Kristeleit RS, Oza AM, et al. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecol Oncol. 2021. PMID: 34602290. doi:10.1016/j.ygyno.2021.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。